News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Transgene appoints Dr. Emmanuelle Dochy as CMO and Dr. Maurizio Ceppi as CSO to drive innovation in cancer immunotherapies. Company progresses clinical pipeline with therapeutic vaccine TG4050 -
-
-
-
COMMUNIQUÉ DE PRESSE
Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC
Transgene announces preclinical proof-of-concept data of oncolytic virus TG6050 published in JITC, showcasing tumor regression and immune remodeling capabilities without systemic toxicity. TG6050 progressing in Phase I trial for NSCLC -